Genitourinary Cancer Archives

Top picks from ASCO GU 2023

VJOncology are thrilled to present our top picks from the the 2023 American Society of Clinical Oncology Genitourinary (ASCO GU)…

Managing urothelial carcinoma with targeted therapies

VJOncology is excited to present the latest data and developments in the bladder cancer field, with comments from Yohann Loriot, Jonathan…

EV-103 Cohort K: Promising data for first-line combination therapy of enfortumab vedotin plus pembrolizumab for patients with urothelial carcinoma

EV-103 (NCT03288545) is a multicohort study investigating the use of the antibody-drug conjugate, enfortumab vedotin, alone or in combination with…

177Lu-PSMA-617 approved for use in patients with PSMA+ mCRPC

As of the 23rd March 2022, the U.S. Food and Drug Administration (FDA) has approved 177Lu-PSMA-617 (a.k.a. Lu 177 Vipivotide…

Top 5 picks from ASCO GU 2022

Catch the latest updates in GU with VJOncology from the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022!

PHS290: a novel scoring algorithm provides a promising approach to screening for prostate cancer in diverse populations

A novel polygenic hazard score (PHS), PHS290, accurately predicts lifetime risks of developing metastatic or terminal prostate cancer across multiple…

Highlights from ESMO 2021

Check out our top picks from ESMO 2021!

Key updates from EAU 2021

VJOncology presents highlights from this year’sEuropean Association of Urology (EAU) Virtual Meeting 2021!

Top picks from ASCO 2021

VJOncology presents highlights from this year’s virtual American Society of Clinical Oncology (ASCO) annual meeting!

First-line therapy in urothelial carcinoma: KEYNOTE-361 & DANUBE

Urothelial carcinoma updates presented at ESMO 2020: JAVELIN Bladder 100

FDA gives mitomycin gel green light for low-grade upper tract urothelial cancer

April 15th saw the Food and Drug Administration (FDA) approval of mitomycin gel (Jelmyto) for the treatment of low-grade upper…

Multi-cancer detection and localization for more than 50 cancer types

The early detection of cancer improves outcomes for patients – in terms of both reducing treatment burden and improving the…

Darolutamide gets the OK in Europe for nmCRPC

Metastatic castration-resistant prostate cancer (mCRPC) has limited treatment options and metastatic growth is associated with increased comorbidities. To put the…

World first in bladder cancer with FDA approval of erdafitinib

Following the release of trial data, the FDA has approved erdafitinib for the treatment of adult patients with fibroblast growth…

Genitourinary Cancer